Intellia Therapeutics develops in vivo CRISPR‑Cas9 gene‑editing medicines that directly correct disease‑causing mutations in patients with severe monogenic disorders. Its platform integrates guide‑RNA design, lipid nanoparticle/AAV delivery, safety screening, and GMP manufacturing to advance candidates from target discovery through clinical trials, aiming for single‑dose curative treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with severe, often rare, genetic disorders have limited therapeutic options, and existing treatments typically address symptoms rather than correcting the underlying DNA mutation. This results in progressive disease, high medical burden, and unmet clinical need for curative interventions.
Solution
Intellia Therapeutics applies CRISPR‑Cas9 genome editing to develop potentially curative medicines that directly modify disease‑causing genes in patients. The company operates a full‑spectrum platform that spans target discovery, guide‑RNA design, delivery vector engineering, preclinical validation, and clinical development. By delivering precise edits in vivo, Intellia aims to halt or reverse disease progression with a single administration, reducing reliance on lifelong symptomatic therapies. Clinical programs such as NTLA‑2001 target hereditary transthyretin amyloidosis, demonstrating the translational pathway from molecular design to patient‑focused trials. The approach integrates rigorous safety assessments, off‑target mitigation, and scalable manufacturing to support regulatory approval and market launch.
Target Audience
Primary customers are patients with severe monogenic diseases and their treating physicians, as well as pharmaceutical partners seeking to license or co‑develop CRISPR‑based gene‑editing therapies.
Features
- Proprietary CRISPR‑Cas9 editing platform optimized for high‑fidelity, on‑target activity in human cells.
- In vivo delivery technologies (e.g., lipid nanoparticle and AAV vectors) engineered for tissue‑specific targeting and efficient cellular uptake.
- Advanced guide‑RNA design pipeline that incorporates computational off‑target prediction and empirical validation.
- Integrated safety program featuring genome‑wide off‑target analysis, immunogenicity profiling, and long‑term follow‑up in animal models.
- Scalable GMP manufacturing process for clinical‑grade CRISPR therapeutics, enabling rapid dose escalation and multi‑patient trials.
- End‑to‑end clinical development framework, from IND filing through Phase 1/2 studies, with real‑time biomarker monitoring.
- Collaborative partnership model that supports co‑development with pharmaceutical companies and academic institutions.
- Patient‑centric trial design, including remote monitoring and patient advocacy integration to accelerate enrollment and retention.